Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Total Current Liabilities (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Total Current Liabilities readings, the most recent being $5.7 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 23.22% to $5.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Mar 2026, up 23.22% year-over-year, with the annual reading at $5.1 million for FY2025, 4.79% down from the prior year.
  • Total Current Liabilities hit $5.7 million in Q1 2026 for DiaMedica Therapeutics, up from $5.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.7 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $3.3 million, with a median of $2.8 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 98.02% in 2024, while the deepest fall reached 7.0% in 2024.
  • DiaMedica Therapeutics' Total Current Liabilities stood at $2.2 million in 2022, then increased by 28.51% to $2.8 million in 2023, then skyrocketed by 93.47% to $5.4 million in 2024, then fell by 4.79% to $5.1 million in 2025, then grew by 12.0% to $5.7 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Total Current Liabilities are $5.7 million (Q1 2026), $5.1 million (Q4 2025), and $5.3 million (Q3 2025).